Legacy Advisory Services’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-24,835
Closed -$2.14M 57
2024
Q4
$2.14M Buy
24,835
+5,560
+29% +$601K 1.82% 16
2024
Q3
$2.3M Buy
19,275
+1,866
+11% +$249K 1.97% 14
2024
Q2
$2.48M Buy
17,409
+11,173
+179% +$1.48M 2.27% 13
2024
Q1
$801K Buy
+6,236
New +$742K 0.76% 21

Other funds holding NVO

Legacy Advisory Services's NVO Position: Q1 2025 in Review

Legacy Advisory Services sold out of Novo Nordisk (NVO) in Q1 2025, closing a stake of 24,835 shares — an estimated $2.14M sold.

Legacy Advisory Services first reported a position in NVO in Q1 2024 and held it in 4 quarters. The position peaked at $2.48M in Q2 2024. 1,528 funds tracked by Wall St. Rank hold NVO as of Q1 2025.

  • Legacy Advisory Services reported no remaining Novo Nordisk position as of Q1 2025 after selling out during the quarter.
  • Legacy Advisory Services sold 24,835 Novo Nordisk shares in Q1 2025, an estimated $2.14M.
  • Legacy Advisory Services first reported a position in Novo Nordisk in Q1 2024 and held it in 4 quarters.
  • Legacy Advisory Services's Novo Nordisk position peaked at $2.48M in Q2 2024.
  • 1,528 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2025.

Based on Legacy Advisory Services's 13F filing for Q1 2025, filed 19 May 2025.